section name header

Pronunciation

gue-sel-KOO-mab

Classifications

Therapeutic Classification: antipsoriatics

Pharmacologic Classification: interleukin antagonists, monoclonal antibodies

Indications

REMS


Action

  • Binds to the p19 protein subunit of the interleukin (IL)-23 cytokine to prevent its interaction with the IL-23 receptor. This cytokine is normally involved in inflammatory and immune responses. Binding to ILs antagonizes their effects, inhibiting the release of proinflammatory cytokines and chemokines.
Therapeutic effects:
  • Decrease in area and severity of psoriatic lesions.
  • Decreased pain and swelling with decreased rate of joint destruction in psoriatic arthritis.
  • Induction of clinical remission of ulcerative colitis.

Pharmacokinetics

Absorption: 49% absorbed following SUBQ administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Broken down by catabolic processes into peptides and amino acids.

Half-Life: 15–18 days

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
SUBQunknown5.5 days8 wk



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects

GI: liver enzymes, diarrhea

Local: injection site reactions

MS: arthralgia

Neuro: headache

Misc: infection, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Plaque Psoriasis and Psoriatic Arthritis

Ulcerative Colitis

Availability

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Tremfya